

Herman W T Van Vlijmen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3312667/publications.pdf>

Version: 2024-02-01

65
papers

3,902
citations

126907

33
h-index

123424

61
g-index

66
all docs

66
docs citations

66
times ranked

5808
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of comparative protein modeling by MODELLER. <i>Proteins: Structure, Function and Bioinformatics</i> , 1995, 23, 318-326.	2.6	1,035
2	Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. <i>Journal of Cheminformatics</i> , 2017, 9, 45.	6.1	219
3	Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. <i>Protein Science</i> , 2006, 15, 949-960.	7.6	160
4	Large scale relative protein ligand binding affinities using non-equilibrium alchemy. <i>Chemical Science</i> , 2020, 11, 1140-1152.	7.4	147
5	Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. <i>MedChemComm</i> , 2011, 2, 16-30.	3.4	138
6	Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL). <i>Journal of Biological Chemistry</i> , 2003, 278, 5444-5454.	3.4	116
7	Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation. <i>ACS Omega</i> , 2016, 1, 293-304.	3.5	108
8	Trends in Antibody Sequence Changes during the Somatic Hypermutation Process. <i>Journal of Immunology</i> , 2006, 177, 333-340.	0.8	102
9	Mutations of the Anti-Müllerian Hormone Gene in Patients with Persistent Müllerian Duct Syndrome: Biosynthesis, Secretion, and Processing of the Abnormal Proteins and Analysis Using a Three-Dimensional Model. <i>Molecular Endocrinology</i> , 2004, 18, 708-721.	3.7	81
10	Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 308-313.	7.1	81
11	Advances and Challenges in Computational Target Prediction. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 1728-1742.	5.4	76
12	The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. <i>Protein Science</i> , 1998, 7, 1124-1135.	7.6	67
13	Identification of Potent and Novel μ 21 Antagonists Using in Silico Screening. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2988-2993.	6.4	67
14	Acylguanidine Beta Secretase 1 Inhibitors: A Combined Experimental and Free Energy Perturbation Study. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 1439-1453.	5.3	67
15	Normal Mode Calculations of Icosahedral Viruses with Full Dihedral Flexibility by Use of Molecular Symmetry. <i>Journal of Molecular Biology</i> , 2005, 350, 528-542.	4.2	66
16	Novel Bicyclic Piperazine Derivatives of Triazolotriazine and Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6218-6229.	6.4	62
17	The Suzuki-Miyaura Cross-Coupling as a Versatile Tool for Peptide Diversification and Cyclization. <i>Catalysts</i> , 2017, 7, 74.	3.5	58
18	An exploration strategy improves the diversity of de novo ligands using deep reinforcement learning: a case for the adenosine A2A receptor. <i>Journal of Cheminformatics</i> , 2019, 11, 35.	6.1	58

#	ARTICLE	IF	CITATIONS
19	Recent Advances in Chemoinformatics. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 1279-1293.	5.4	57
20	A Novel Database of Disulfide Patterns and its Application to the Discovery of Distantly Related Homologs. <i>Journal of Molecular Biology</i> , 2004, 335, 1083-1092.	4.2	56
21	A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 1708-1713.	6.4	52
22	Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A _{2A} Receptor. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 1737-1746.	5.4	49
23	Analysis of Calculated Normal Modes of a Set of Native and Partially Unfolded Proteins. <i>Journal of Physical Chemistry B</i> , 1999, 103, 3009-3021.	2.6	48
24	Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development. <i>PLoS ONE</i> , 2011, 6, e27518.	2.5	47
25	Extending kinome coverage by analysis of kinase inhibitor broad profiling data. <i>Drug Discovery Today</i> , 2015, 20, 652-658.	6.4	46
26	Identifying Novel Adenosine Receptor Ligands by Simultaneous Proteochemometric Modeling of Rat and Human Bioactivity Data. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7010-7020.	6.4	45
27	Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5563-5579.	5.4	45
28	Structure-Based Site of Metabolism Prediction for Cytochrome P450 2D6. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6098-6105.	6.4	44
29	Predicting Binding Free Energies of PDE2 Inhibitors. The Difficulties of Protein Conformation. <i>Scientific Reports</i> , 2018, 8, 4883.	3.3	43
30	Molecular Modeling of Drug-Transporter Interactions—An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 818-835.	4.7	43
31	Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data. <i>PLoS Computational Biology</i> , 2013, 9, e1002899.	3.2	42
32	Predicting Activity Cliffs with Free-Energy Perturbation. <i>Journal of Chemical Theory and Computation</i> , 2019, 15, 1884-1895.	5.3	37
33	Normal mode analysis of large systems with icosahedral symmetry: Application to (Dialanine) ₆₀ in full and reduced basis set implementations. <i>Journal of Chemical Physics</i> , 2001, 115, 691-698.	3.0	32
34	A classification of disulfide patterns and its relationship to protein structure and function. <i>Protein Science</i> , 2004, 13, 2045-2058.	7.6	31
35	Accuracy and Precision of Alchemical Relative Free Energy Predictions with and without Replica-Exchange. <i>Advanced Theory and Simulations</i> , 2020, 3, 1900195.	2.8	30
36	DrugEx v2: de novo design of drug molecules by Pareto-based multi-objective reinforcement learning in polypharmacology. <i>Journal of Cheminformatics</i> , 2021, 13, 85.	6.1	30

#	ARTICLE	IF	CITATIONS
37	Large-Scale Validation of Mixed-Solvent Simulations to Assess Hotspots at Protein-Protein Interaction Interfaces. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 784-793.	5.4	29
38	Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. <i>Protein Engineering, Design and Selection</i> , 2006, 19, 317-324.	2.1	27
39	Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations. <i>Chemical Science</i> , 2021, 12, 5511-5516.	7.4	22
40	Cheminformatics. <i>Communications of the ACM</i> , 2012, 55, 65-75.	4.5	21
41	The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena. <i>Drug Discovery Today</i> , 2016, 21, 97-102.	6.4	21
42	In search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptor. <i>Journal of Computer-Aided Molecular Design</i> , 2016, 30, 863-874.	2.9	20
43	The Need of Industry to Go FAIR. <i>Data Intelligence</i> , 2020, 2, 276-284.	1.5	20
44	Chemogenomics Approaches for Receptor Deorphanization and Extensions of the Chemogenomics Concept to Phenotypic Space. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1964-1977.	2.1	18
45	Identification of Allosteric Modulators of Metabotropic Glutamate 7 Receptor Using Proteochemometric Modeling. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 2976-2985.	5.4	18
46	Application of ESMACS binding free energy protocols to diverse datasets: Bromodomain-containing protein 4. <i>Scientific Reports</i> , 2019, 9, 6017.	3.3	18
47	The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. <i>FEBS Journal</i> , 2003, 270, 3610-3618.	0.2	17
48	Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling. <i>Journal of Cheminformatics</i> , 2019, 11, 15.	6.1	17
49	Limitations of Ligand-Only Approaches for Predicting the Reactivity of Covalent Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 4220-4227.	5.4	15
50	Mining protein dynamics from sets of crystal structures using "consensus structures". <i>Protein Science</i> , 2010, 19, 742-752.	7.6	14
51	A knowledge-based forcefield for protein-protein interface design. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 70, 1540-1550.	2.6	13
52	Interacting with GPCRs: Using Interaction Fingerprints for Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2053-2060.	5.4	12
53	Quantitative prediction of selectivity between the A1 and A2A adenosine receptors. <i>Journal of Cheminformatics</i> , 2020, 12, 33.	6.1	10
54	Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. <i>Antiviral Therapy</i> , 2009, 14, 273-283.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Assessment of the Fragment Docking Program SEED. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4881-4893.	5.4	9
56	Application of the ESMACS Binding Free Energy Protocol to a Multi- ϵ -Binding Site Lactate Dehydrogenase A Ligand Dataset. <i>Advanced Theory and Simulations</i> , 2020, 3, 1900194.	2.8	9
57	Structure-activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5245-5248.	2.2	8
58	Chemical space screening around Phe3 in opioid peptides: Modulating $\hat{\mu}$ versus $\hat{\nu}$ agonism by Suzuki-Miyaura cross-couplings. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2320-2323.	2.2	4
59	Successive Statistical and Structure-Based Modeling to Identify Chemically Novel Kinase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4283-4295.	5.4	4
60	The Impact of Experimental and Calculated Error on the Performance of Affinity Predictions. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 703-717.	5.4	4
61	Divide and Conquer. Pocket-Opening Mixed-Solvent Simulations in the Perspective of Docking Virtual Screening Applications for Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 533-543.	5.4	3
62	Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4664-4672.	5.4	2
63	FEP+ calculations predict a stereochemical SAR switch for first-in-class indoline NIK inhibitors for multiple myeloma. <i>Future Drug Discovery</i> , 2020, 2, .	2.1	2
64	The performance of ensemble-based free energy protocols in computing binding affinities to ROS1 kinase. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
65	Identification of novel inhibitors of rat Mrp3. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105813.	4.0	1